DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Patent 7,435,734 protects ISENTRESS, DUTREBIS, and ISENTRESS HD, and is included in four NDAs.
Protection for ISENTRESS has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has forty-nine patent family members in thirty-four countries.
Summary for Patent: 7,435,734
|Title:||N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase|
|Abstract:||N-substituted 5-hydroxypyrimidin-6-one-4-carboxamides of formula: ##STR00001## are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.|
|Inventor(s):||Crescenzi; Benedetta (Rome, IT), Gardelli; Cristina (Ariccia, IT), Muraglia; Ester (Rome, IT), Nizi; Emanuela (Siena, IT), Orvieto; Federica (Rome, IT), Pace; Paola (Rome, IT), Pescatore; Giovanna (Cosenza, IT), Petrocchi; Alessia (Rome, IT), Poma; Marco (Grosseto, IT), Rowley; Michael (Axa, IT), Scarpelli; Rita (Rome, IT), Summa; Vincenzo (Velletri, IT)|
|Assignee:||Istituto di Ricerche di Biologia Molecolare P. Angeletti S.p.A. (Pomezia, IT)|
Patent Claim Types:|
see list of patent claims
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||TE||Type||RLD||RS||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Patented / Exclusive Use||Submissiondate|
|Merck Sharp Dohme||ISENTRESS||raltegravir potassium||POWDER;ORAL||205786-001||Dec 20, 2013||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|Merck Sharp Dohme||ISENTRESS||raltegravir potassium||TABLET, CHEWABLE;ORAL||203045-001||Dec 21, 2011||RX||Yes||No||Start Trial||Start Trial||Y||Start Trial|
|Merck Sharp Dohme||ISENTRESS||raltegravir potassium||TABLET, CHEWABLE;ORAL||203045-002||Dec 21, 2011||RX||Yes||Yes||Start Trial||Start Trial||Y||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>TE||>Type||>RLD||>RS||>Patent No.||>Patent Expiration||>Product||>Substance||>Delist Req.||>Patented / Exclusive Use||>Submissiondate|
|Country||Patent Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
|>Country||>Patent Number||>Estimated Expiration||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration|